Trial reportBritish journal of haematology2026
Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.
Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Elderly transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM) often cannot tolerate standard-dose lenalidomide-dexamethasone (Rd), leading to frequent dose reductions. We evaluated an upfront frailty-adapted Rd dosing strategy using the revised Myeloma Comorbidity Index (R-MCI) in this frail population. In a multicentre phase II trial, patients ≥70 years classified as intermediate-fit (R-MCI 4-6) or frail (R-MCI ≥7) received Rd with starting doses stratified by frailty (intermediate-fit: lenalidomide 25 mg + dexamethasone 20 mg; frail: lenalidomide 15 mg + dexamethasone 10 mg). Two-year progression-free survival (PFS) was the primary end-point. Secondary end-points included overall survival (OS), overall response rate (ORR) and safety. Among 70 enrolled patients (69 evaluable; median age 80), 54% were intermediate-fit and 46% frail. ORR was 86.9%, with ≥VGPR (very good partial response) in ~36% of both groups. Two-year PFS was 37.4% (95% confidence interval [CI]: 26.9%-57.8%; median PFS 15.6 months) and 2-year OS was 63.0% (95% CI: 51.6%-77.0%), with no statistically significant differences between intermediate-fit and frail patients in this exploratory analysis. Grade ≥3 neutropenia occurred in 24.3% and 40.6% of intermediate-fit and frail patients, respectively, while grade ≥3 infectious complications were observed in 10.8% and 12.5%, respectively, without significant differences between groups. The frailty-guided, dose-attenuated Rd regimen in elderly unfit NDMM yielded high response rates and clinically meaningful survival with manageable toxicity. These exploratory findings suggest that frail patients may achieve outcomes approaching those of intermediate-fit patients despite reduced starting doses, warranting confirmation in adequately powered prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.